Impaired cardiac sympathetic innervation and myocardial perfusion are related to lethal arrhythmia: Quantification of cardiac tracers in patients with ICDs

Journal of Nuclear Medicine

Volumn 51, Issue 8, 2010, Pages 1241-1249

  Nishisato, Kimio ^a   Hashimoto, Akiyoshi ^b   Nakata, Tomoaki ^b,c   Doi, Takahiro ^b   Yamamoto, Hitomi ^b   Nagahara, Daigo ^d   Shimoshige, Shinya ^b   Yuda, Satoshi ^b   Tsuchihashi, Kazufumi ^b   Shimamoto, Kazuaki ^b  

^a Muroram City General Hospital   (Japan)

^b SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Hokkaido Prefectural Esashi Hospital   (Japan)

^d Obihiro Kosei General Hospital   (Japan)

Author keywords

Implantable cardioverter defibrillator; Lethal arrhythmias; Metaiodo benzylguanidine imaging; Myocardial perfusion imaging; Sudden cardiac death

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 123; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; SOTALOL; SPIRONOLACTONE; TETROFOSMIN; TETROFOSMIN TC 99M; TRACER; DIAGNOSTIC AGENT; ORGANOPHOSPHORUS COMPOUND; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX; TECHNETIUM TC 99M 1,2 BIS(BIS(2 ETHOXYETHYL)PHOSPHINO)ETHANE; TECHNETIUM TC 99M 1,2-BIS(BIS(2-ETHOXYETHYL)PHOSPHINO)ETHANE;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED STUDY; DEFIBRILLATION; DEFIBRILLATOR; DIAGNOSTIC VALUE; DRUG UPTAKE; ELECTRIC SHOCK; FEMALE; HAZARD RATIO; HEART; HEART ARRHYTHMIA; HEART DEATH; HEART FAILURE; HEART INDEX; HEART INNERVATION; HEART MUSCLE PERFUSION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; LETHALITY; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; REST; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUMMATED RATING SCALE; SYMPATHETIC INNERVATION; ADRENERGIC SYSTEM; AGED; ANALYSIS OF VARIANCE; BIOASSAY; CORONARY ARTERY BLOOD FLOW; ELECTROCARDIOGRAPHY; FOLLOW UP; INNERVATION; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; SCINTISCANNING; SUDDEN DEATH;

3-IODOBENZYLGUANIDINE; ADULT; AGED; ANALYSIS OF VARIANCE; ARRHYTHMIAS, CARDIAC; CORONARY CIRCULATION; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; ELECTROCARDIOGRAPHY; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; HEART; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; ORGANOPHOSPHORUS COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOPHARMACEUTICALS; SYMPATHETIC NERVOUS SYSTEM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 77956199184     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.074971     Document Type: Article

References (40)

1. Bristow MR, Saxon LA, Boehmer J, et al. Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140-2150.
2. Knight BP, Goyal R, Pelosi F, et al. Outcome of patients with nonischemic dilated cardiomyopathy and unexplained syncope treated with an implantable defibrillator. J Am Coll Cardiol. 1999;33:1964-1970.
3. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). The CASCADE Investigators. Am J Cardiol. 1993;72: 280-287.
4. Kadish A, Dyer A, Daubert JP, et al. Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151-2158.
5. Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article - a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). Circulation. 2002;106: 2145-2161. (Pubitemid 35192824)
6. Sweeney MO, Ruskin JN. Mortality benefits and the implantable cardioverter-defibrillator. Circulation. 1994;89:1851-1858.
7. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med. 2005;353:1471-1480.
8. Eguchi M, Tsuchihashi K, Hotta D, et al. Technetium-99m sestamibi/tetrofosmin myocardial perfusion scanning in cardiac and noncardiac sarcoidosis. Cardiology. 2000;94:193-199.
9. Eguchi M, Tsuchihashi K, Nakata T, Hashimoto A, Shimamoto K. Right ventricular abnormalities assessed by myocardial single-photon emission computed tomography using technetium-99m sestamibi/tetrofosmin in right ventricle-originated ventricular tachyarrhythmias. J Am Coll Cardiol. 2000;36: 1767-1773.
10. Gradel C, Jain D, Batsford WP, Wackers FJ, Zaret BL. Relationship of scar and ischemia to the results of programmed electrophysiological stimulation in patients with coronary artery disease. J Nucl Cardiol. 1997;4:379-386.
11. 123I-meta-iodobenzylguanidine scintigraphy. Circulation. 1994;89:667-683.
12. Arora R, Ferrick KJ, Nakata T, et al. I-123 MIBG imaging and heart rate variability analysis to predict the need for an implantable cardioverter defibrillator. J Nucl Cardiol. 2003;10:121-131.
13. Nakata T, Wakabayashi T, Kyuma M, Takahashi T, Tsuchihashi K, Shimamoto K. Cardiac metaiodobenzylguanidine activity can predict the long-term efficacy of angiotensin-converting enzyme inhibitors and/or beta-adrenoceptor blockers in patients with heart failure. Eur J Nucl Med Mol Imaging. 2005;32:186-194.
14. Kyuma M, Nakata T, Hashimoto A, et al. Incremental prognostic implications of brain natriuretic peptide, cardiac sympathetic nerve innervation, and noncardiac disorders in patients with heart failure. J Nucl Med. 2004;45:155-163. (Pubitemid 47628373)
15. Wakabayashi T, Nakata T, Hashimoto A, et al. Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac death. J Nucl Med. 2001;42:1757-1767.
16. Nakata T, Wakabayashi T, Kyuma M, et al. Prognostic implications of an initial loss of cardiac metaiodobenzylguanidine uptake and diabetes mellitus in patients with left ventricular dysfunction. J Card Fail. 2003;9:113-121.
17. Nakata T, Nagao K, Tsuchihashi K, Hashimoto A, Tanaka S, Iimura O. Regional cardiac sympathetic nerve dysfunction and the diagnostic efficacy of metaiodobenzylguanidine tomography in stable coronary artery disease. Am J Cardiol. 1996;78:292-297.
18. Nakata T, Miyamoto K, Doi A, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol. 1998;5:579-590.
19. Nakata T, Shimamoto K, Yonekura S, et al. Cardiac sympathetic denervation in transthyretin-related familial amyloidotic polyneuropathy: detection with iodine-123-MIBG. J Nucl Med. 1995;36:1040-1042.
20. Nagahara D, Nakata T, Hashimoto A, et al. Predicting the need for an implantable cardioverter defibrillator using cardiac metaiodobenzylguanidine activity together with plasma natriuretic peptide concentration or left ventricular function. J Nucl Med. 2008;49:225-233.
21. Nakata T, Katagiri Y, Odawara Y, et al. Two- and three-dimensional assessments of myocardial perfusion and function by using technetium-99m sestamibi gated SPECT with a combination of count- and image-based techniques. J Nucl Cardiol. 2000;7:623-632.
22. Hashimoto A, Nakata T, Wakabayashi T, et al. Validation of quantitative gated SPECT and an automated scoring system for the assessment of regional left ventricular systolic function. Nucl Med Commun. 2002;23:887-898.
23. Myerburg RJ, Kessler KM, Bassett AL, Castellanos A. A biological approach to sudden cardiac death: structure, function, and cause. Am J Cardiol. 1989;63:1512-1516.
24. Matsunari I, Schricke U, Bengel FM, et al. Extent of cardiac sympathetic neuronal damage is determined by the area of ischemia in patients with acute coronary syndromes. Circulation. 2000;101:2579-2585.
25. Kjekshus J. Arrhythmia and mortality in congestive heart failure. Am J Cardiol. 1990;65:42I-48I.
26. Willich SN, Maclure M, Mittleman M, Arntz HR, Muller JE. Sudden cardiac death: support for a role of triggering in causation. Circulation. 1993;87:1442-1450.
27. 123I-mIBG scintigraphy to predict inducibility of ventricular arrhythmias on cardiac electrophysiology testing: a prospective multicenter pilot study. Circ Cardiovasc Imaging. 2008;1: 131-140.
28. Maisel WH, Sweeney MO, Stevenson WG, Ellison KE, Epstein LM. Recalls and safety alerts involving pacemakers and implantable cardioverter-defibrillator generators. JAMA. 2001;286:793-799.
29. Gomes JA, Cain ME, Buxton AE, Josephson ME, Lee KL, Hafley GE. Prediction of long-term outcomes by signal-averaged electrocardiography in patients with unsustained ventricular tachycardia, coronary artery disease, and left ventricular dysfunction. Circulation. 2001;104:436-441.
30. Bloomfield DM, Steinman RC, Namerow PB, et al. Microvolt T-wave alternans distinguishes between patients likely and patients not likely to benefit from implanted cardiac defibrillator therapy: a solution to the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II conundrum. Circulation. 2004;110:1885-1889.
31. Brendorp B, Elming H, Jun L, et al. QT dispersion has no prognostic information for patients with advanced congestive heart failure and reduced left ventricular systolic function. Circulation. 2001;103:831-835.
32. La Rovere MT, Pinna GD, Maestri R, et al. Short-term heart rate variability strongly predicts sudden cardiac death in chronic heart failure patients. Circulation. 2003;107:565-570.
33. Shusterman V, Goldberg A, London B. Upsurge in T-wave alternans and nonalternating repolarization instability precedes spontaneous initiation of ventricular tachyarrhythmias in humans. Circulation. 2006;113:2880-2887.
34. Inoue H, Zipes DP. Result of sympathetic denervation in the canine heart: supersensitivity that may be arrhythmogenic. Circulation. 1987;75:877-887.
35. Romeo F, Pelliccia F, Cianfrocca C, Cristofani R, Reale A. Predictors of sudden death in idiopathic dilated cardiomyopathy. Am J Cardiol. 1989;63: 138-140. (Pubitemid 19018965)
36. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355:260-269.
37. Böcker D, Bänsch D, Heinecke A, et al. Potential benefit from implantable cardioverter-defibrillator therapy in patients with and without heart failure. Circulation. 1998;98:1636-1643.
38. Goldberger JJ, Cain ME, Hohnloser SH, et al. American Heart Association/ American College of Cardiology Foundation/Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death: a scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention. J Am Coll Cardiol. 2008;52:1179-1199.
39. Tsuchimochi S, Tamaki N, Tadamura E, et al. Age and gender differences in normal myocardial adrenergic neuronal function evaluated by iodine-123-MIBG imaging. J Nucl Med. 1995;36:969-974.
40. 123I-MIBG scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: design of two prospective multicenter international trials. J Nucl Cardiol. 2009;16:113-121.